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Abstract: The extracellular matrix (ECM) is a complex and specialized three-dimensional
macromolecular network, present in nearly all tissues, that also interacts with cell surface receptors
on joint resident cells. Changes in the composition and physical properties of the ECM lead to
the development of many diseases, including osteoarthritis (OA). OA is a chronic degenerative
rheumatic disease characterized by a progressive loss of synovial joint function as a consequence of
the degradation of articular cartilage, also associated with alterations in the synovial membrane and
subchondral bone. During OA, ECM-degrading enzymes, including urokinase-type plasminogen
activator (uPA), matrix metalloproteinases (MMPs), and a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTSs), cleave ECM components, such as fibronectin (Fn), generating
fibronectin fragments (Fn-fs) with catabolic properties. In turn, Fn-fs promote activation of these
proteinases, establishing a degradative and inflammatory feedback loop. Thus, the aim of this review
is to update the contribution of ECM-degrading proteinases to the physiopathology of OA as well as
their modulation by Fn-fs.
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1. Introduction
Osteoarthritis (OA) is the most prevalent arthritic disease affecting the joints. While mainly
related to aging, it is also associated with a diversity of risk factors including genetic predisposition,
epigenetic factors, gender, obesity, exercise, work-related injury, and trauma. Irreversible and gradual
loss of the articular cartilage remains the fundamental feature of OA pathophysiology [1–4]. However,
in the course of the disease, all the joint tissues including synovium and bone undergo physical,
functional, and metabolic alterations that comprise different cellular types as well as components of
the extracellular cellular matrix (ECM). The ECM is a complex and specialized three-dimensional
macromolecular network, present in nearly all tissues, which also interacts with cell surface receptors on
joint resident cells. It is secreted, assembled, and modeled by the surrounding cells, providing physical
support and organization to tissues. ECM is involved in many cell functions, providing cells with
chemical and mechanical signals to regulate cell proliferation, survival, migration, and differentiation.
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However, changes in the composition and physical properties of the ECM lead to the development of
many diseases, including cancer and rheumatic diseases, such as OA and rheumatoid arthritis (RA),
among others [5,6]. Moreover, cell stress and ECM degradation promote maladaptive healing reactions,
including inflammatory pathways of innate and adaptive immunity [7]. The loss of the biomechanical
properties of cartilage induced by prior injuries or increased loading is the most significant feature in the
initiation and progression of OA. Among the fibrillary components of ECM, the glycoprotein fibronectin
(Fn) is an important member that acts as a bridging molecule in matrix assembly and cell–matrix
interfaces. During the development of OA, tissue proteolysis and injury induce ECM degradation
generating Fn fragments (Fn-fs), among other catabolic mediators, that promote inflammation and
degradation by the induction of cytokine [8] and proteinase expressions [5]. This review focuses on the
emerging issues related to the role of Fn-fs in the inflammatory cascade through the stimulation of
urokinase-type plasminogen activator (uPA), matrix metalloproteinases (MMPs), and a disintegrin
and metalloproteinase with thrombospondin motifs (ADAMTSs) proteinases in OA. The mechanisms
underlying these proteinases are also discussed.
2. Fibronectin
Fibronectin is an adhesive glycoprotein, widely distributed in most ECM that regulates different
cellular functions such as adhesion, motility, growth, differentiation, and opsonization [9,10]. It is a
dimeric protein formed by two polypeptide chains with multiple repeated modular structures joined
by two anti-parallel S-S bonds at the C-terminus. Each monomer of the Fn dimer has a molecular
weight of 230–270 Da, and it is composed of three different types of modules: twelve Fn type I (FnI),
two Fn type II (FnII) and fifteen to seventeen Fn type III (FnIII) [11–15] (Figure 1A). FnI, FnII, and FnIII
domains are made up of 40, 60, and 90 amino acids, respectively. Twenty different Fn proteins are
observed in humans even though Fn is encoded by a single 75 kb gene [16]. This protein diversity
is obtained by alternative splicing of two type FnIII exons, called extra domains A and B (EIIIA and
EIIIB) and by a segment connecting two other FnIII repeats, FnIII14 and FnIII15, called the type III
connecting segment (IIICS) or V domain, that can be assembled in four different ways or fully omitted.
The multimodular structure and intermodular regions permit flexibility of the Fn molecule, which
is involved in regulating its functions [13,15,16]. The different specific domains of Fn can interact
with multiple binding partners, for example cell-surface receptors or other ECM components such
as heparin, collagen, and proteoglycans. Fn is structured into four functional domains including
a N-terminal domain (FnI1-9 plus FnII1-2), which binds Fn to heparin, collagen or fibrin; a central
binding domain (FnII1-12) is responsible in part for Fn binding with the cells through the interaction
with different integrins; and a C-terminal binding domain (FnIII12-14 plus IIICS plus FnI10-12) that
also has other cell-binding sites, heparin- or fibrin-binding sites and the disulfide bridges responsible
for Fn dimerization. For all of these reasons, Fn is considered to be a key molecule in the control
of cellular regulatory processes and an essential scaffolding protein to preserve and maintain tissue
organization [15].
There are two forms of Fn based on its solubility: plasma Fn, the soluble form, and cellular
Fn, the water-insoluble form. The latter appears on cell surfaces and in the ECM of various tissues
such as the synovial membrane and cartilage, but also in the synovial fluid. Moreover, plasma Fn
has been reported to be integrated into the ECM with cellular Fn. Plasma Fn and cellular Fn have
different structures and forms of assembly in three-dimensional networks (Figure 1B). Whereas plasma
Fn lacks the alternatively spliced EIIIA and EIIIB regions, cellular Fn has different parts of these
domains. In addition, only one subunit of plasma Fn possesses an IIICS segment. Taking these data into
consideration, the number of different cellular Fn isoforms that can be generated is much higher than
plasma Fn, due to the presence of alternative variants in the EIIIA, EIIIB, and IIICS segments [15,16].
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Figure 1. Fibronectin (Fn) and Fn fragments (Fn-fs) primary structure. (A) the schematic shows a 
representation of an Fn dimer and its interactions with different cell–surface receptors or other 
extracellular matrix (ECM) components such as heparin, collagen, and proteoglycans. Twelve Fn type 
I (FnI), two Fn type II (FnII) and fifteen constitutively expressed and two alternatively spliced Fn type 
III (FnIII) are indicated. The extra domains A and B (EIIIA and EIIIB) and the segment connecting two 
other FnIII repeats called the type III connecting segment (IIICS) or V domain are also shown. The 
scissors symbolize protease-sensitive regions of Fn and corresponding enzymes most commonly 
responsible for cleavage at these regions; (B) structural differences between plasma Fn and cellular 
Fn are shown; (C) the figure shows the different fragments of Fn and the structural domains that 
remain in each of them after breakage with proteolytic enzymes, adapted from [9,15–17]. 
There are two forms of Fn based on its solubility: plasma Fn, the soluble form, and cellular Fn, 
the water-insoluble form. The latter appears on cell surfaces and in the ECM of various tissues such 
as the synovial membrane and cartilage, but also in the synovial fluid. Moreover, plasma Fn has been 
reported to be integrated into the ECM with cellular Fn. Plasma Fn and cellular Fn have different 
structures and forms of assembly in three-dimensional networks (Figure 1B). Whereas plasma Fn 
lacks the alternatively spliced EIIIA and EIIIB regions, cellular Fn has different parts of these 
domains. In addition, only one subunit of plasma Fn possesses an IIICS segment. Taking these data 
into consideration, the number of different cellular Fn isoforms that can be generated is much higher 
than plasma Fn, due to the presence of alternative variants in the EIIIA, EIIIB, and IIICS segments 
[15,16]. 
Plasma Fn is synthesized by hepatocytes and directly released into circulation in a soluble, 
compact and inactive form. Blood plasma Fn levels increase after inflammation, major trauma, or 
pathologies such as atherosclerosis, ischaemic heart disease, and stroke [18–21]. Many cell types 
produce cellular Fn, including fibroblasts, endothelial cells, myocytes, chondrocytes, and synovial 
cells [15]. The different isoforms of cellular Fn are tissue-dependent, temporally regulated, and cell-
Figure 1. Fibronectin (Fn) and Fn fragments (Fn-fs) primary structure. (A) the schematic shows
a representation of an Fn dimer and its interactions with different cell–surface receptors or other
extracellular matrix (ECM) components such as heparin, collagen, and proteoglycans. Twelve Fn type I
(FnI), two Fn type II (FnII) and fifteen constitutively expressed and two alternatively spliced Fn type
III (FnIII) are indicated. The extra domains A and B (EIIIA and EIIIB) and the segment connecting
two other FnIII repeats called the type III connecting segment (IIICS) or V domain are also shown.
The scissors symbolize protease-sensitive regions of Fn and corresponding enzymes most commonly
responsible for cleavage at these regions; (B) structural differences between plasma Fn and cellular Fn
are shown; (C) the figure shows the different fragments of Fn and the structural domains that remain in
each of them after breakage with proteolytic enzymes, adapted from [9,15–17].
Plasma Fn is synthesized by hepatocytes and directly released into circulation in a soluble,
compact and inactive form. Blood plasma Fn levels increase after inflammation, major trauma, or
pathologies such as atherosclerosis, ischaemic heart disease, and stroke [18–21]. Many cell types produce
cellular Fn, including fibroblasts, endothelial cells, myocytes, chondrocytes, and synovial cells [15].
The different isoforms of cellular Fn are tissue-dependent, temporally regulated, and cell-type-specific.
These isoforms regulate the properties of the ECM and consequently modulate different cellular
processes. Under certain pathological conditions, some of the isoforms are exceptionally synthesized by
cells or undergo a considerable increase in their synthesis. For instance, the isoform EIIIA is increased
in synovial fluid of RA joints and correlates with the progression of joint destruction [22]. Another
example is the presence of different synovial IIICS (+) isoforms, which vary their expression levels
according to the degree of cartilage degeneration in OA [23]. An additional important fact to take
into account is that the presence or absence of the different EIIIA, EIIIB, or IIISC regions affects the
orientation and flexibility of the rest of the FnIII modules, altering the three-dimensional structure of
the Fn and therefore its interactions during matrix assembly that can modulate Fn-cell signaling [15,24].
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The functional form of Fn in vivo is its fibrillary state; thus, Fn molecules must be assembled into
supermolecular fibers that form an interconnected network [14]. The presence of cells is necessary
for Fn-matrix assembly, which occurs in several stages. First connections between Fn and cells are
established through surface receptors such as integrins. Then, Fn is unfolded resulting in the exposure
of Fn binding sites that allow Fn-Fn intermolecular interactions. Finally, the Fn-matrix assembly
is formed. Both the expression of Fn and its assembly is regulated by a multitude of molecules in
a cell-specific manner [15]. The Fn matrix assembly occurs at times of dynamic tissue remodeling,
formation or repair and is essential during embryonic development [14].
Fibronectin Fragments
Proteases play a major role during infection or inflammation and are responsible for generating
different Fn-fs. Fn-fs have different functions in tissues undergoing active remodeling and can also
serve as self-modulators of Fn activity [17]. Some effects of Fn-fs may be predicted by knowing where
proteolysis occurs and therefore which fragments are generated. The functions of Fn-fs may differ from
those of the entire Fn molecule, given that some of the domains are lost after proteolysis, secondary
and tertiary structures of the molecule may be altered or active encrypted sites may appear. In addition,
size reduction and altered secondary configuration may allow greater penetration into the tissues [25].
The Fn-fs described are classified as follows: the 70 Da N-terminal Fn-fs (including a 24–32 Da
N-terminal heparin/fibrin-binding Fn-fs and a 40–60 Da N-terminal gelatin/collagen-binding Fn-fs),
the central cell-binding domain Fn-fs, and the C-terminal heparin binding Fn-fs (Figure 1C).
The 70 Da N-terminal Fn-fs is a large fragment less frequent than the other two N-terminal Fn-fs,
as has an interior protease-sensitive region. In fact, this can only be produced by limited exposure
to cathepsin D. The size of the N-terminal heparin/fibrin-binding Fn-fs can range from 24–32 Da.
This fragment has affinity for heparin and fibrin and can form a fibrillar matrix through binding with
each other at their amino-terminal end. These interactions are important in metastasic invasion or
synovial invasion of cartilage. The 40–60 Da N-terminal gelatin/collagen-binding Fn-fs, in addition to
collagen or gelatin, also has affinity for C1q and tPA [17]. The central cell-binding domain Fn-fs contains
an Arg-Gly-Asp (RGD) sequence, responsible for the cell-adhesive properties through the binding
to different integrins. The size of this Fn-fs depends on different isoforms generated by alternatively
spliced EIIIA and EIIIB regions [17,26]. For the same reason as the previous fragment, the size of the
C-terminal heparin-binding Fn-fs is variable thanks to the alternative spliced IIICS region. This last
fragment is responsible for cell binding through integrins and the binding to proteoglycan [17]. Little
is known about the involvement of the last two fragments in different pathologies.
Both Fn and its degradation fragments trigger cellular responses through binding to their surface
receptors such as different integrins, TLRs, and CD44. In this way, they are able to activate different
signaling pathways such as the MAPK pathway or transcription factors such as NF-κB or AP-1 [9,27–31].
In addition, they are able to establish a positive feedback with the Wnt/β-catenin pathway through
integrins and MAPK signaling [32,33].
3. Osteoarthritis
Osteoarthritis is a chronic degenerative rheumatic disease, characterized by a progressive loss
of synovial joint function as a consequence of the degradation of articular cartilage and associated
with alterations in synovial membranes and subchondral bone [3,34,35]. Currently, it is considered
the clinical endpoint of heterogeneous disorders with common clinical, pathological and radiological
characteristics, resulting in the degeneration of one or more joints [3,36,37]. The main joints damaged
are the knee, hand, spine, foot and hip [38,39]. Although it is usually an age-related disease, it is not a
direct and inevitable consequence of aging. Rather, OA is also associated with other risk factors that
culminate in joint dysfunction.
OA is the most prevalent disease in developed countries and the main cause of incapacity in
the elderly population. In a recent review about the socioeconomic cost of OA, it has been estimated
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between 0.25% and 0.50% of the gross domestic product of a country [40]. The majority of available
therapies focus on relieving symptoms, but there are challenges to slowing the progression of the
disease. Therefore, it is important to find new therapeutic targets aimed at the development of new
drugs for the treatment of OA to mitigate the disease impact [41,42].
During the development of OA, degeneration of all joint constituents including cartilage, synovial
membrane, bone, bone marrow and ligaments occurs [36,43]. The biological imbalance and the
mechanical stress lead to a pathological situation with altered chondrocyte behavior releasing
inflammatory mediators and ECM destruction enzymes [35,44–46]. All of this together with the
inhibition of cartilage biosynthesis [47] increases the fragility and loss of cartilage integrity. Regarding
synovial tissue, synovitis is characterized by synovial hypertrophy and hyperplasia, with increased
proliferation of synovial fibroblasts (SF) and macrophage, angiogenesis and inflammatory infiltration
of mononuclear cells. Although synovitis is usually localized and may even be asymptomatic [48],
synovial activation causes the release of cytokines, chemokines, proteases, growth factors and
other inflammatory mediators that accelerate the progression of the disease [36,49,50]. In addition,
the subchondral bone also seems to play an important role in the onset and progression of OA, by
releasing catabolic mediators that promote an altered metabolism in chondrocytes [39,51].
In this scenario, the degeneration of the ECM, the main component of most synovial joint tissues,
contributes to the pathological process. The ECM of articular cartilage is composed of a network
of type II collagen, lesser amounts of other important collagens (VI, IX, X, XI), proteoglycans and
non-collagenous proteins. During the progression of OA, chondrocytes reshape the ECM of the cartilage
under inflammatory conditions causing numerous changes in its mechanical function associated with
increased catabolic activity [52]. This disruption of matrix equilibrium leads to progressive loss
of cartilage tissue in which extracellular matrix proteases, including ADAMTSs, MMPs, and uPA,
among others, play a crucial role [35,44–46]. Products derived from the degradation of the ECM such
as collagen, Fn or its degradation fragments, induce the activation of joint cell receptors, initiating
a series of signaling pathways that converge in the production of new activation and destruction
mediators [49,53]. Knowledge of these proteases is essential to understand OA pathophysiology.
3.1. Proteases in Osteoarthritis
Proteases are enzymes responsible for proteolytic cleavage mediated by hydrolysis of peptide
bonds into the target molecule. They are involved in several biological processes, as well as in
the processing and activation of precursors implicated in ECM remodeling, the immune system,
development, and apoptosis. Overall, proteases can be divided into exopeptidases, when they cleave
substrates at the N-terminal or C-terminal positions, and endopeptidases or proteinases, which cleave
peptide bonds in the middle of the molecule. In turn, proteinases are classified according to the
catalytic mechanism involved in the process of hydrolysis, where they can act intracellularly or
extracellularly (Scheme 1). Among them, some extracellular proteinases, including serine proteinases
and metalloproteinases, play a main role in the degradative and inflammatory processes that take
place in OA development, as they are involved in cartilage destruction, bone erosion and synovial
inflammation. As a consequence, they induce the release of ECM components to the OA joint, which in
turn induce the expression of proteinases, therefore aggravating the pathology [54,55].
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uPA is implicated in the activation of the zymogen plasminogen to plasmin. It is mainly involved
in tissue remodeling and inflammation in physiologic conditions, but its deregulation is also related to
several pathologies [57,62–65]. uPA is composed of a signal peptide followed by a N-terminal fragment
(ATF) for receptor binding, which in turn consists of an epidermal growth factor (EGF)-like domain
and a Kringle domain, and a C-terminal catalytic serine proteinase domain [54,65,66] (Figure 2A).
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(GPCRs) and the EGF-receptor. Other ligands for uPAR are the ECM protein vitronectin and the
high molecular weight kininogen. On the other hand, the uPA system is negatively regulated by
plasminogen activator inhibitors (PAI) or serpins. The main PAIs are PAI-1 (or serpinE1) and PAI-2
(or serpinB2). In addition, α2 antiplasmin also regulates the system through the blockage of plasmin
activity [57,65] (Figure 3).
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3.1.2. MMPs
MMPs and ADAMTSs belong to the metzincins superfamily, characterized as zinc-dependent
enzymes responsible for ECM protein turnover, degrading type II collagen, and aggrecan [9,58]. Their
action is regulated by endogen inhibitors, the tissue inhibitors of metalloproteinases (TIMP-1 to 4).
While TIMP-1 and TIMP-2 are the major inhibitors of MMP action, TIMP-3 is mainly involved in the
inhibition of aggrecanases [85,86]. Altered levels of MMPs, ADAMTSs and TIMPs have been described
in OA patients [87–89].
First described in 1962 due to their collagenolytic action in tadpole metamorphosis, the MMP
family is composed of 25 members, which are involved in ECM remodeling, as well as in the processing
of other proteinases and their inhibitors, cell surface receptors, and growth factors. In addition,
they participate in several physiological processes, including cell adhesion, proliferation, migration,
apoptosis, and healing [87,90,91]. MMPs are divided into five main groups according to their substrate,
structure, and cell location: collagenases, gelatinases, stromelysins, matrilysins, and membrane-type
matrix metalloproteinases (MT-MMPs) [55,87,91–93] (Table 1).
Table 1. Classification of human matrix metalloproteinases (MMPs).
Family Enzyme Main Substrates
MMP-1 (collagenase-1) Collagen I, II, III, VII, VIII, X, and XI, gelatin, entactin, tenascin, aggrecan, fibronectin, vitronectin,myelin basic protein, ovostatin, casein, MMP-2, MMP-9, proMMPs
MMP-8 (collagenase-2) Collagen I, II, and III, fibronectin, prostaglandins, aggrecan, ovostatin
Collagenases
MMP-13 (collagenase-3) Collagen I, II, III, IV, IX, X and XIV, gelatin, tenascin, plasminogen, osteonectin, fibronectin,aggrecan, casein
MMP-18 Collagen, gelatin
MMP-2 (gelatinase A) Collagen I, III, IV, V, VII and X, gelatin, fibronectin, laminin, aggrecan, elastin, vitronectin, tenascin,myelin basic protein
Gelatinases
MMP-9 (gelatinase B) Collagen IV, V, XI, elastin, aggrecan, decorin, laminin, entactin, myelin basic protein, casein
MMP-3 (stromelysin-1) Collagen III, IV, V, IX, X and XI, gelatin, aggrecan, elastin, fibronectin, vitronectin, laminin, entactin,tenascin, decorin, myelin basic protein, ovostatin, casein, osteonectin, proMMPs
MMP-10 (stromelysin-2) Collagen III, IV and V, gelatin, elastin, fibronectin, aggrecan, casein
MMP-11 (stromelysin-3) Gelatin, fibronectin, collagen IV, laminin, elastin, casein, prostaglandinsStromelysins
MMP-27 Gelatin
MMP-7 Collagen I and IV, gelatin, elastin fibronectin, vitronectin, laminin, entactin, tenascin, aggrecan,myelin, proMMP-1, proMMP-2, proMMP-9 transferrin, caseinMatrilysins
MMP-26 Collagen IV, gelatin, fibronectin, fibrinogen, pro-MMP9
MMP-14 (MT1-MMP) Collagen I, II and III, gelatin, fibronectin, tenascin, vitronectin, laminin, entactin, aggrecan,vibronectin, pro-MMP2
MMP-15 (MT2-MMP) Fibronectin, tenascin, entactin, laminin, aggrecan, gelatin, vibronectin, pro-MMP2
MMP-16 (MT3-MMP) Collagen III, gelatin, fibronectin, casein, laminin, pro MMP-2
MMP-17 (MT4-MMP) Gelatin, fibrinogen, pro MMP-2
MMP-24 (MT5-MMP) Fibronectin, gelatin, proteoglycans, pro-MMP2
MT-MMPs
MMP-25 (MT6-MMP) Collagen IV, gelatin, fibronectin, proteoglycans, pro-MMP2
MMP-12 Collagen I, V and IV, gelatin, elastin, fibronectin, vitronectin, laminin, entactin, osteonectin,aggrecan, myelin, vitronectin, fibrinogen
MMP-19 Collagen I and IV, gelatin, lamin, entactin, fibronectin, aggrecan
MMP-20 Amelogenin, aggrecan
MMP-21 Not defined
MMP-23 Gelatin
Other MMPs
MMP-28 Caseine
MMPs are classified in families according to their main substrates, adapted from [56,91].
MMPs are found in all animal kingdoms. The MMPs identified in vertebrates are structurally
similar to each other, indicating that they arose by duplication of a common ancestral gene followed
by divergent evolution [94]. The phylogenetic analysis comparing human MMPs with their ortholog
genes in the chordate Ciona intestinalis, recently recognized as Ciona robusta [95] and considered the
closest invertebrate relatives of vertebrates, revealed the presence of six MMPs in this species: MMP-21,
MMP-24, MMP-24-2 MMP-14, MMP-14-2, and only one equivalent to gelatinase MMP-9 like [96].
In general, MMPs are composed of a signal peptide essential for the maturation and enzyme
release from the cell, a pro-domain responsible for keeping the enzyme inactive, a catalytic domain
containing the Zn2+ atom that provides the enzymatic activity, a binding domain of variable range that
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is lost in some MMPs, and a hemopexin domain that is also lost in some MMPs, lending substrate
specificity in addition to the interaction with some inhibitors and cell receptors [55,87,92,93] (Figure 2B).
Due to their proteolytic activity, the MMPs are strongly regulated and require the action of other
enzymes for removal of the pro-domain and activation, including MT-MMPs, cathepsin B, plasmin,
uPA, and tPA. This activation is usually extracellular, but can also occur at the cell surface, such
as for MMP-13 and MMP-2, or intracellularly in the Golgi complex, as in the case of MMP-11 and
MT-MMPs [97].
An exacerbated activation of MMPs can lead to the development of several pathologies, including
cancer, cardiovascular diseases, and inflammatory and/or autoimmune diseases, such as OA and RA.
In this regard, increased levels of MMPs have been detected in the synovial tissue and cartilage of OA
and RA patients [59,88,89,93,98–100].
Collagenases
Among the MMPs involved in OA, the collagenases play a key role in degrading collagen
from the cartilage ECM. This group is composed of MMP-1 (collagenase-1), MMP-8 (collagenase-2),
MMP-13 (collagenase-3), and MMP-18, which can be released by chondrocytes, as well as by SF and
synovial macrophages in the joint microenvironment. Both MMP-1 and MMP-13 are central to OA
pathology. While MMP-1 is predominantly produced by SF and is involved in early stages of the disease
contributing to the destruction of the cartilage surface, MMP-13, mainly released by chondrocytes,
is essential in successive phases of ECM remodeling [59,101].
The role of MMP-13 is crucial for OA development and progression, as it is the main factor
involved in the degradation of type II collagen, along with other ECM components, including
aggrecan [58,59,87,92,102,103]. In addition to articular cartilage degradation, MMP-13 also causes
its erosion and ulceration. Furthermore, it is involved in synovial inflammation, inducing synovial
hyperplasia with mononuclear cell infiltration in the joint [103]. Increased levels of MMP-13 have been
detected in cartilage from OA patients, where it is associated with a greater destruction [104–106],
as well as in SF from RA patients, correlating with uPA levels [107]. MMP-13 is also present in SF
and synovial fluid from OA and RA patients [108–111], where cytokines such as IL-1β and other
inflammatory mediators are involved in the induction of its expression [80,92].
Gelatinases
Increased levels of other MMPs have also been described in OA and other rheumatic disease,
including MMP-2 and MMP-9 [59]. MMP-2 and MMP-9 belong to the group of gelatinases, which have
a broad range of substrate specificity. The gelatinases not only degrade gelatins, but also other ECM
components, including Fn and different types of collagen. In this regard, MMP-2 is able to degrade
type I, II, and III collagens, but with a lower activity than collagenases. Gelatinases are produced by
mesenchymal cells, macrophages and mononuclear cells from peripheral blood, but can also be released
from activated and tumoral cells. As a special feature of their structure, gelatinases have three Fn type
II repeat domains in their catalytic domain, which facilitate substrate binding and degradation [87,99].
Among the gelatinases, MMP-9 or gelatinase B is involved in physiological and pathological
processes, being implicated in tumoral cell survival, as well as in cardiovascular, degenerative,
autoimmune, and inflammatory diseases, where MMP-9 activates pro-inflammatory mediators
reciprocally. This gelatinase is characterized by a flexible O-glycosylated domain between the catalytic
and hemopexin domains, which is essential for its function [92,112]. MMP-9 levels in synovial fluid
from OA and RA patients are related to MMP-13 and uPA, taking part in the progression of the
disease [107].
Other MMPs
Stromelysins show a wide range of substrate specificity, including proteoglycans, Fn, elastin and
laminin, among other ECM components [92]. Among them, MMP-3 is one of the MMPs most expressed
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in OA cartilage, which decreases in late phases of the disease [113]. Increased levels of MMP-3 have
been described in arthritic diseases [59], suggesting an important role of this MMP in the release of
proteoglycans from cartilage [114].
Regarding matrilysins, MMP-7 is able to degrade different ECM components, also including
proteoglycans [115]. Higher levels of MMP-7 have been observed in OA synoviocytes compared to
controls in a rat model of knee OA [116]. In addition, overexpression of this MMP has been detected in
human OA cartilage [115].
Finally, the MT-MMPs subfamily of MMPs is characterized by a transmembrane domain at the
C-terminus. The MT-MMPs act at the cell surface and are able to activate other MMPs, suggesting
a role in ECM degradation as well. Among them, MT1-MMP also has collagenolytic activity, and is
expressed in human articular cartilage, synovial membrane, and osteoclast-like cells in bone resorption.
MT3-MMP is highly expressed in OA and RA synovium as well. On the other hand, MT2- and
MT4-MMP do not seem to be involved in joint destruction [92,117].
3.1.3. ADAMTSs
The ADAMTS superfamily includes secreted metalloproteases, ADAMTS proteases, as well as
ADAMTS-like proteins (ADAMTSLs), structurally-linked secreted glycoproteins that lack catalytic
activity. Members of both families contribute to varied morphogenetic processes during embryonic
development, and connective tissue maintenance. Research on ADAMTSLs proteins is less advanced,
although it seems that they are functionally related to ADAMTSs, such as in the turnover and assembly
of fibrillin microfibrils [118,119].
The ADAMTS family includes zinc-dependent endopeptidases that play an essential role in
developmental processes and in the maintenance of homeostasis by remodeling ECM [120]. Alterations
in ADAMTS expression are also related to the development of certain inflammatory, arthritic, vascular
and neurodegenerative pathologies, as well as cancer [121]. The first ADAMTS was discovered in the
late 1990s [122].
There are 19 ADAMTS genes in humans, designated ADAMTS1 through ADAMTS20, where
ADAMTS5 and ADAMTS11 represent the same gene. The biology of a protease is based on the
substrates on which they perform their proteolytic activity. Therefore, the remaining 18 members of
proteases are sub-classified according to their specific substrate in five subgroups [123–125] (Table 2).
Phylogenetically, in invertebrates, only one ADAMTS, called Gon-1, with a common ancestor within
the same clade as ADAMTS9 and ADAMTS20 in mammals, has been described in nematodes [126].
The phylogenetic analysis comparing human ADAMTSs with their ortholog genes in the chordate C.
robusta, revealed different evolutionary branches of ADAMTS proteases that originated by duplication
of ancestral genes represented by six C. robusta orthologs [125]. It has also been proposed that, after
duplication, vertebrate paralogues have mainly developed through sub-functionalization, rather than
neo-functionalization. Moreover, data from vertebrates support the ADAMTS gene family evolution
through duplication processes across metazoans, complemented by a burst of amplification through
vertebrate whole genome duplication events [127]. Therefore, there are robust data to speculate that
the core genes of protease activity have been conserved in the phylogeny and predict the functional
sub-classification of human ADAMTSs.
ADAMTSs are composed of a proteinase domain and a C-terminal auxiliary domain, which
provides the substrate specificity, allows the interaction with the ECM, regulates its activity and
ultimately determines its location. The proteinase domain is composed of a signal peptide, a pro-domain,
a catalytic domain and a disintegrating domain. The auxiliary domain is formed by a variable number
of repeated motifs of thrombospondin type 1 (TSP-1), a cysteine-rich region and a spacer region. The
carboxyl terminal may vary depending on the enzyme, and may contain other TSP-1 domains and
motifs [123,128] (Figure 2C).
Multiple isoforms of ADAMTSs generated by alternative splicing processes and post-translational
modifications of glycosylation and proteolysis, involved in their secretion, location, activation and
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catalytic function, have been reported [123,129,130]. Like MMPs, ADAMTSs are synthesized inactively
and released as zymogens. These zymogens undergo N-terminal processing, which removes the
signal peptide in addition to the pro-domain, and allows accurate protein processing and secretion.
The pro-domain usually contains at least one binding site for furin or furin-like proprotein convertases,
which are responsible for intracellular or extracellular activation of the enzyme by its elimination.
Nevertheless, certain aggrecanases do not need the removal of the pro-domain to be active. Once
secreted, ADAMTSs may also undergo processing at the C-terminal end, where the spacer region is
involved [123,131–133].
Table 2. Classification of human a disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTSs).
Family Enzyme Main Substrates
Agrecanases and proteoglycanases
ADAMTS1
ADAMTS4
ADAMTS5
ADAMTS8
ADAMTS9
ADAMTS15
ADAMTS20
Proteoglycans:
aggrecan, versican, brevican,
neurocan, fibromodulin, decorin,
carboxylmethylated transferrin
COMP proteinases ADAMTS7ADAMTS12 COMP
Procollagen
N-peptidases
ADAMTS2
ADAMTS3
ADAMTS14
Procollagen
von-Willebrand factor proteinases ADAMTS13 von-Willebrand coagulation factor
Other ADAMTS
ADAMTS6
ADAMTS10
ADAMTS16
ADAMTS17
ADAMTS18
ADAMTS19
Not defined
ADAMTSs are classified in families according to their main substrates, adapted from [56].
Aggrecanases and Proteoglycanases
The aggrecanases and proteoglycanases subgroup includes a series of ADAMTSs that are able
to break chondroitin sulphate proteoglycans that bind to hyaluronic acid [134]. The aggrecan is
one of the main components of the cartilage ECM, which also protects collagen from degradation.
The loss of ECM aggrecans originating in the early stages of OA is one of the key events in the
development of the disease [85,123]. In fact, it can be observed as degradation products in synovial
fluid from patients with OA and RA [135,136]. In this process, aggrecanases take on an essential role.
Although there are also MMPs and other proteases capable of degrading aggrecans, in contrast to
aggrecanases, they cannot cleave it at the highly-conserved sequence of the protein nucleus involved
in the pathogenesis of OA, NITEGE373-374ARGSV of the intraglobular domain, between Glu373 and
Ala374 [85,123]. This proteolysis results in the generation of the ARGSV and NITEGE neoepitopes,
which are elevated in cartilage from OA and AR patients [137,138]. Moreover, this subgroup of
ADAMTSs can also cleave versican, brevican, and neurocan.
ADAMTS1 breaks aggrecan and versican and is expressed in cartilage and synovium. Data about
its expression in OA are controversial; some authors reported an increased expression in cartilage [139]
whereas recent results using qRT-PCR showed that ADAMTS1 is downregulated in joint synovial
tissues [140].
Regarding ADAMTS4 and ADAMTS5, the first critical step in OA development is the loss of
cartilage aggrecans mediated by these ADAMTSs. Although ADAMTS5 is the main mouse aggrecanase,
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there is disagreement about which of the two aggrecanases is the most important in humans. Both are
involved in the pathogenesis of OA, where they play an important role through the degradation of
aggrecan, mainly in the initial and final stages [123,141]. Some studies consider ADAMTS4 the main
factor implicated in OA because its levels are increased in the cartilage of these patients, correlating with
a greater degradation of this tissue. However, other authors reported ADAMTS4 and -5 expressions
in cartilage and SF, where ADAMTS5 was more expressed in SF from healthy donors (HD) than in
OA, while ADAMTS4 gene expression was similar in both [33,50]. In addition, in vitro studies have
shown that ADAMT5 activity is higher than that of ADAMTS4 [142]. It has been described that the
expression of ADAMTS4 can be induced with different pro-inflammatory mediators, such as IL-1β or
TNFα, while some authors point out that ADAMTS5 is constitutive [143,144]. Nevertheless, different
studies indicated that both ADAMTSs can be induced [145,146].
Studies on ADAMTS8, ADAMTS9, ADAMTS15, and ADAMTS20 are less common. ADAMTS8
has aggrecanase activity. It is expressed in healthy cartilage and an increased expression in human OA
synovium has been described. ADAMTS9 and -20 cleave aggrecan and versican, respectively. They are
both expressed in healthy cartilage, being upregulated in OA. Regarding ADAMTS15, it degrades
aggrecan and versican, and its expression in OA cartilage is controversial [147].
COMP Proteinases
ADAMTS7 and ADAMTS12 are the only ADAMTSs that have a mucin domain, to which the
condroitin sulphate chains are bound, giving them proteoglycan characteristics [148]. They also
contain a protease and lacunin (PLAC) motif at its C-terminal end, with six conserved cysteine residues.
Its processing depends on furins and ends in the extracellular space. The importance of these ADAMTSs
lies in their ability to degrade COMP [149], a ECM protein that contributes to the maintenance of
cartilage stability through its interaction with other components, such as aggrecan, type II collagen
or Fn [149–151]. Fragments derived from their degradation in cartilage, synovial fluid and serum
have been described in patients with OA and RA [152]. The TSP-1 motifs of the C-terminal end of the
ADAMTS7 and -12 allow them to interact with COMP [149,153]. In turn, COMP is associated with
the precursor of granulin-epithelin (GEP), which inhibits the activity of ADAMTS7 and -12. Elevated
levels of GEP in the synovial tissue of patients with OA and RA have also been described [149,154].
Likewise, alpha-2-macroglobulin (α2M) is another substrate of ADAMTS7 and -12, also involved in
their regulation. On the other hand, ADAMTS12 is also capable of degrading the aggrecan of the ECM,
but with a much smaller capacity than the ADAMTS4 and -5 aggrecanases [155]. ADAMTS7 and
-12 are involved in the pathogenesis of different diseases, including rheumatic and vascular diseases
and cancer [123,149]. Both enzymes are expressed in the joint, including cartilage, bone and synovial
tissue. ADAMTS7 and -12 also participate in the inhibition of chondrogenesis, acting as targets of the
parathyroid hormone-related protein [149,153]. High levels of these ADAMTSs have been described in
patients with OA and RA [88,156,157], which can be induced by pro-inflammatory stimuli, although in
the case of ADAMTS12, this depends on the cell type involved [158]. Moreover, COMP degradation in
OA cartilage explants is inhibited by neutralizing antibodies against both ADAMTSs [155].
ADAMTS7 and ADAMTS12 have been detected in joint cartilage with a higher expression in
OA than in HD. Moreover, we have described the expression and release of both ADAMTSs in SF,
which represent a source of metalloproteinases for the perpetuation of cartilage damage [33,50].
Procollagen N-Propeptidases
Synthesis of collagen fibers is a complex process. Fibrillar collagens are secreted as pro-molecules
composed of a large central triple helical domain extended by propeptides at both extremities. These
amino- and carboxy-propeptides are then cleaved by procollagen N-proteinases and C-proteinases,
respectively, reducing the solubility of the collagen molecules, which induces the spontaneous
assemblage into lengthened collagen fibrils.
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ADAMTS2, ADAMTS3, and ADAMTS14 are responsible for the cleavage of the N-terminal
propeptide of the fibrillary collagens. ADAMTS2 was first described in dermatosparaxis, a cattle
disease characterized by extreme skin fragility [159]. Subsequently, dermatosparaxis Ehlers–Danlos
syndrome (dEDS) was identified as the equivalent in humans, characterized by the presence of different
mutations in the ADAMTS2 gene [160].
An elevated expression of ADAMTS2 has been identified in all type I collagen-rich tissues
from fetal calf such as skin, bones, tendons and aorta, supporting its significance in type I collagen
assembly [161]. Increased expression of ADAMTS2 has been described in OA cartilage [147]. Moreover,
this ADAMTS has been demonstrated to exhibit effective anti-angiogenic activity [162].
ADAMTS3 is mainly expressed in cartilage, where it colocalizes with type II procollagen,
and in the nervous system [163,164]. It is more effective than ADAMTS2 in processing type II
pro-collagen [163]. An augmented expression of this protease along with ADAMTS14 has also been
described in OA [165,166]. In this regard, two polymorphisms have been identified in the ADAMTS14
gene associated with an increased risk of knee OA in woman [167,168]. However, the role played by
these proteases in rheumatic pathologies is still quite unknown and more studies are needed.
von-Willebrand Factor Proteinase
ADAMTS13 is a von-Willebrand factor-cleaving proteinase [123]. Regarding OA, no data have been
described about this ADAMTS; only its upregulation in human OA synovium has been reported [89].
Other ADAMTSs
Finally, another group of ADAMTSs with an unknown substrate have been called “orphan”
proteases. ADAMTS6, ADAMTS10, and ADAMTS18 are expressed in OA cartilage. ADAMTS6 and
-10 have been involved in the regulation of cell–cell junctions and focal adhesion [169]. ADAMTS6
transforms procollagen to collagen [170]. An inguinal hernia genetic susceptibility locus near the
ADAMTS6 gene has been reported, indicating that collagen deregulation could be involved in
the progress of inguinal hernias [171]. Mutations in the ADAMTS10 gene have been reported in
Weill–Marchesani syndrome (WMS), a disorder characterized by abnormalities in the eye and skeletal
development [172]. Finally, regarding ADAMTS16 and -17, although no data correlating these ADAMTs
to rheumatic pathologies have been found, they are involved in bone development and collagen
processing. Thus, three mutations in the ADAMTS17 gene have been identified supporting a role
in the development of a connective-tissue disorder that is similar to WMS [172]. Genetic variants of
ADAMTS16 and -19 associated with inherited hypertension and premature ovarian failure, respectively,
have been reported [121].
Only by understanding the full spectrum of proteinases expressed in the joint and their biological
functions in this location will it be possible to design strategies to selectively target pathological
tissue destruction.
4. Fibronectin and Fibronectin Fragments in Osteoarthritis
High levels of Fn have been described in the superficial layer of OA articular cartilage. Moreover,
elevated levels of Fn accumulate in the inflamed synovial tissue and in the articular cartilage of RA joints.
Enhanced levels of Fn are also observed in the synovial fluid, being 55% higher than levels in normal
plasma [9,173–175]. In the course of these rheumatic diseases, in addition to the enhanced amounts
of Fn in the joints, an exacerbated activation of Fn-degrading proteases has been described. In fact,
increased levels of Fn-fs have been reported in the synovial fluid of OA and RA patients [9,17,176,177].
These fragments are included within the term matrikines, peptides originated from the fragmentation
of ECM proteins that play an important role in both health and disease [178]. The activity of proteases
is crucial during infection and inflammation, being responsible for the generation of different Fn-fs.
Fn-fs have properties not present in native Fn, and are the main candidates for the maintenance
of cartilage destruction and synovial tissue inflammation in OA. Thus, 29-, 45-, 120-, and 200 Da
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Fn-fs derived from Fn have been found in OA cartilage and synovial fluid, where they stimulate the
production of various inflammatory cytokines, such as TNFα and IL-1β [114]. In addition, increased
release of 29 Da N-terminal heparin-binding, 50 Da N-terminal gelatin-binding, and 110-140 Da
C-terminal heparin-binding Fn-fs have been detected in bovine injured cartilage explants compared
to controls [179]. More recently, it has been reported that 29 Da N-terminal heparin-binding Fn-fs
inhibited autophagy through modifying localization of HMGB1 in human articular chondrocytes [180].
Along with OA, another musculoskeletal pathology with a huge worldwide prevalence is low back
pain, which is generated by the degenerative disc disease, among other causes [181]. The degenerative
progression in intervertebral discs is generally identified as intervertebral disc degeneration (IVD) [182].
IVD and OA share characteristics and properties such as cell physiology and ECM of the nucleus
pulposus and articular cartilage. It has been suggested that, in acute stages, IVD is accompanied
by loss of joint space, subchondral sclerosis, and osteophytes, comparable to OA in the articular
joint. As occurs in OA, in IVD local inflammation is the result of mechanical overloading or low
grade systemic inflammation, being characterized by increased levels of inflammatory cytokines.
Moreover, this inflammatory cascade produces the degradation of ECM with the involvement of
different proteinases including MMP-1–3, -7–10, and -12–14, as well as ADAMTS4 and -5. As a result,
in both diseases, a chronic inflammation loop is established that degenerates both intervertebral disc
and articular joint [183]. An additional element of similarity is the role that Fn plays in both pathologies.
In this sense, an increased expression of Fn and Fn-fs has been reported in human spontaneously
degenerative discs [184]. Moreover, the high levels of Fn-fs have been related with disc degeneration
mediated by upregulation of MMP-3 and MMP-13 [29]. Ruel et al. have described that adult IVD
tissues contains many Fn-fs that were absent from the infant disc tissue (6). The highest amount
of FN-fs was present in the moderately degenerative discs, as well as in the initial phases of disc
degeneration, before observable changes to the disc tissue arise, thus suggesting that Fn-fs play a
significant role in the initiation and evolution of disc degeneration [185].
Baker et al. proposed a mathematical model showing that positive and negative feedback
monitoring the degree of cytokine production can regulate either the pre-disposition to OA or the
initiation of OA. Moreover, they proposed that manipulation of cytokines, proteinases and Fn-fs levels
could be used to treat OA and other related pathologies, suggesting that multiple treatment targets
may be essential to break or slow disease progression [186].
In the next section, we describe the multi-target effect of different Fn-fs in the modulation of
ECM-degrading enzymes in OA.
4.1. Effect of Fibronectin Fragments in the Profile of OA Matrix-Remodeling Proteinases
During OA, ECM degrading enzymes induce the release of damage-associated molecular patterns
(DAMPs) with catabolic properties, including Fn-fs. These Fn-fs act as pro-inflammatory mediators in
a positive feedback loop inducing the expression of pro-inflammatory cytokines, nitric oxide (NO),
and other inflammatory mediators, as well as proteinases, degrading ECM components, and therefore
promoting inflammation and cartilage destruction in OA [9,176,177]. In this regard, different authors
have described the induction of proteinases mediated by Fn-fs in chondrocytes and SF, including uPA,
MMPs, and ADAMTSs [33,80,114,174,187] (Figure 4).
4.1.1. Fn-fs Modulate the uPA System and Induce MMP Expression
Deregulation of the uPA system is related to the development of several pathologies including
OA [39,54,55,92]. During this disease, Fn-fs are released to the joint microenvironment as a consequence
of ECM degradation. In this respect, it has been described that 45 Da N-terminal gelatin-binding
Fn-fs increase uPA expression and activity and uPAR production in OA-SF [80]. Furthermore, 29 Da
N-terminal heparin-binding Fn-fs also increases uPA levels in bovine articular cartilage [114]. Moreover,
40- to 60 Da N-terminal gelatin-binding Fn-fs are associated with the binding of immunoglobulins
and complement proteins to inflammation sites, as well as with the activity of tPA and uPA [17,80].
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In addition, these fragments have been related to proteoglycanase activity, associated with MMPs or
ADAMTSs [17,33].
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Figure 4. Schematic representation of the interaction of Fn with proteinases in the context of OA
pathology. In a situation of inflammation and cartilage damage, Fn cleavage from the cartilage ECM
promotes the release of Fn-fs to the joint microenvironment. Binding of Fn-fs to their receptors (integrins
and TLRs) activates different signaling pathways increasing the expression of proteinases (uPA, MMPs,
and ADAMTSs). In turn, active proteinases degrade the cartilage ECM inducing a feed-back loop of
inflammation and cartilage degradation.
As mentioned above, binding of active uPA to uPAR induces the activation of plasminogen
to plasmin, which in turn activates MMPs. In this regard, in addition to the uPA system, 45 Da
N-terminal gelatin-binding Fn-fs also increase the production of MMP-9 and MMP-13 in OA-SF
culture supernatants [80]. Moreover, these fragments induce MMP-3 and MMP-13 synthesis in porcine
cartilage [188]. Elevated release of MMPs and proteoglycans, as well as increased proteoglycan
degradation and induction of NO and catabolic cytokines, has been observed in bovine articular
cartilage [114]. In addition, 50% removal of articular cartilage proteoglycans mediated by Fn-fs has
been described in rabbit knee joints [189]. This proteoglycan depletion is mainly associated with the
activity of MMP-3, increased by 29 Da N-terminal heparin-binding, 50 Da N-terminal gelatin-binding,
and 140 Da central cell-binding Fn-fs in bovine cartilage. MMP-3 in turn degrades Fn, generating new
Fn-fs in a positive feedback loop [114,179,190]. Furthermore, 29 Da N-terminal heparin-binding Fn-fs
also enhance gelatinase expression in bovine cartila e [114,174]. These Fn-fs have been involved in
the sti ul tion of the expression of catabolic factors through the TLR2-dependent signaling pathway.
Thus, the expo ure to 29 Da N-terminal heparin-binding Fn-fs from synovial fluid of OA atie ts,
incre sed MMP-1, MMP-3, and MMP-13 expression in primary chondrocytes, where TLR2 kn ckdown
significantly blocked the synovial fluid-induced MMP stimulation [28]. Moreover, involvement of α5
integrins has been shown in cartilag proteoglycan degradation. In this respect, α5 integrins seem to
be implicated in the N-terminal heparin- and gelatin-binding, central cell-binding, and C-terminal
heparin-binding Fn-fs induction of proteoglycan loss, promoting cartilage destruction in bovine
cartilage [25,174,191].
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Central cell-binding Fn-fs are able to stimulate MMP-1 and MMP-3 expression in rabbit SF [187],
as well as MMP-3 in rabbit chondrocytes [192]. Moreover, 120 Da central cell-binding Fn-fs increase
MMP-13 in human chondrocytes, with the involvement of α5β1 integrins [193,194]. These 120 Da Fn-fs
also induce collagenase expression in rabbit SF [195]. In addition, 29 Da N-terminal heparin-binding
and 140 Da central cell-binding Fn-fs, increase the tissue inhibitor of metalloproteinases TIMP-1 in
bovine articular cartilage [114].
Finally, C-terminal heparin-binding Fn-fs induce MMP-3 and MMP-13 production in bovine
cartilage [196], MMP-1, MMP-2, MMP-9, and MMP-13 in human cartilage [197], as well as MMP-1,
MMP-3, and MMP-13 in RA-SF [198]. Moreover, these Fn-fs also increase type II collagen cleavage in
human and bovine cartilages, mainly mediated by MMP-13 [196,197].
While Fn is less active than its degradation products, it is also able to induce the expression of
metalloproteinases in some contexts. In this regard, Fn increases MMP-9 production in human and
murine macrophages [199]. Furthermore, Fn induces MMP-2 expression in human prostate cancer
cells [200]. MMPs in turn cleave Fn, generating Fn-fs. Therefore, MMP-1, MMP-3, MMP-13, and
MMP-14 degrade Fn generating 70 Da Fn-fs, where MMP-13 and -14 were the most effective. Moreover,
MMP-13 and -14, are also able to generate 52-, 40-, 32-, and 29 Da Fn-fs in articular cartilage from
bovine knee joints [201]. In addition, MMP-8, -9 and -12 also cleave Fn in human articular cartilage,
where MMP-12 seems to be the main metalloproteinase [202].
4.1.2. Fn-fs Modifies ADAMTS Expression and Signaling
The 45 Da N-terminal gelatin-binding Fn-fs has been shown to increase aggrecanase levels in
SF. Specifically, these Fn-fs induce ADAMTS4 expression and protein production in HD- and OA-SF,
ADAMTS5 expression and protein production in OA-SF, as well as aggrecanase activity in OA-SF, and
GAGs release in HD- and OA-SF [33]. In addition, these 45 Da Fn-fs induce aggrecan degradation and
the generation of aggrecanase-derived neoepitopes in porcine cartilage [188]. Induction of ADAMTS5
mediated by 29 Da N-terminal heparin-binding Fn-fs has also been described in human and bovine
chondrocytes [203,204]. Furthermore, these ADAMTSs, primarily ADAMTS4, are also involved
in Fn cleavage in human articular cartilage [202,205]. On the other hand, the 40 Da C-terminal
heparin-binding Fn-fs is able to inhibit the aggrecanase activity of ADAMTS4 in human chondrocytes,
suggesting a positive effect of this Fn-fs by avoiding cartilage degradation [206].
Regarding COMP-degrading ADAMTSs, 45 Da N-terminal gelatin-binding Fn-fs also increase
ADAMTS7 expression and protein production in HD- and OA-SF, ADAMTS12 expression, and protein
production in OA-SF, and COMP degradation in HD- and OA-SF [33]. On the other hand, concerning
ECM assembly, COMP interacts with Fn, with a predominant binding site at the N-terminal domain of
Fn [150].
In relation to other ADAMTSs, ADAMTS16 inhibits Fn fibrillogenesis and cleaves Fn, releasing
a 30 Da N-terminal heparin-binding Fn-fs, which in turn, upregulates MMP-3, which is also able to
cleave Fn, generating new Fn-fs and inducing a positive degradative feedback loop in an epithelial cell
line [207]. Additionally, ADAMTS9 is involved in Fn turnover and fibrillogenesis in ECM remodeling
during mouse embryogenesis [208].
Finally, regarding signaling pathways implicated in ADAMTS expression, 45 Da N-terminal
gelatin-binding Fn-fs induce Runx2 activation in HD- and OA-SF and Wnt/β-catenin signaling
in OA-SF [33,50]. Furthermore, Fn is a target of Wnt signaling in mouse embryonic lung
morphogenesis [209] and, in turn, the canonical Wnt pathway is involved in Fn and metalloproteinase
expression in RA-SF [210], suggesting a feedback loop between Fn and β-catenin [211].
5. Conclusions
• Fibronectin is a component of the ECM essential to its assembly, which also regulates some
cellular functions. However, cleavage of fibronectin in pathological conditions releases fibronectin
fragments with pro-inflammatory and degradative properties.
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• Fibronectin fragments mainly released from cartilage ECM during osteoarthritis induce the
expression of different proteinases, such as uPA, MMPs, and ADAMTSs. These proteinases
degrade several ECM components, including the type II collagen and the aggrecan.
• Overexpressed proteinases in the osteoarthritis joint microenvironment cleave fibronectin,
therefore releasing new fibronectin fragments and promoting a feed-back loop of degradation and
inflammation in the pathology.
• The study of fibronectin and proteinases in pathological conditions is important for the design of
new strategies using them as potential therapeutic targets for the treatment of osteoarthritis, to
control not only the symptoms but also the progression of the disease.
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ADAMTSLs ADAMTS-like proteins
ADAMTSs A disintegrin and metalloproteinase with thrombospondin motifs
DAMPs Damage-associated molecular patterns
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EGF Epidermal growth factor
Fn Fibronectin
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GPCRs G protein-coupled receptors
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MMPs Matrix metalloproteinases
MT-MMPs Membrane-type matrix metalloproteinases
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SF Synovial fibroblasts
TIMP Tissue inhibitors of metalloproteinases
TLR2 Toll-like receptor 2
tPA Tissue-type plasminogen activator
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